USA flag logo/image

An Official Website of the United States Government

Not Available

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96554
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
N43ES201000005
Solicitation Year:
N/A
Solicitation Topic Code:
NIEHS
Solicitation Number:
N/A
Small Business Information
HIGH THROUGHPUT GENOMICS, INC.
3430 E. Global Loop TUCSON, AZ 85706-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Not Available
Agency: HHS
Contract: N43ES201000005
Award Amount: $149,371.00
 

Abstract:

This Phase I proposal will develop and validate assays to measure the metabolism of compounds  and their affect on liver cells using a multiplexed gene expression assay platform, the quantitative Nuclease  Protection Assay (qNAP¿) that can measure the expression of up to 100 mRNA and miRNA and is a  simple, robust and highly precise assay that provides high sample throughput. Two cell systems will be  evaluated, HepaRG cell line and primary hepatocytes. The genes associated with metabolism are known,  and they will be incorporated into the assay. miRNA associated with metabolism are not known, and they  will be identified using a whole transcriptome miRNA assay. The final screening assay will incorporate both  mRNA and miRNA, and will be performed in a 384-well format. The data generated will be dose response  data so that differential metabolism can be assessed based of what genes are regulated as well as the EC50  at which they are regulated.  The significance is that this assay will enable the screening of compounds for metabolism on a cell system  that mirrors in vivo liver function and assess all the pathways by which compounds are metabolized,  including Phase I and Phase II metabolism, and transporters, so that not only will the primary compound  effects be monitored, but also the effect of metabolites produced by the cell system will be assessed. This  will be done ins a single assay, something that cannot be done with enzyme assays. Acquiring dose  response data and EC50's at the level of gene expression is highly novel, and brings gene expression up to  the level where metabolism enzyme assays are today.

Principal Investigator:

Kirk Collamer
Small Business Information at Submission:

HIGH THROUGHPUT GENOMICS, INC.
3430 E. Global Loop TUCSON, AZ 85706-

EIN/Tax ID: 860912294
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No